Artem Plus 15/90 Suspension 60ml

Description

Artem Plus is an oral antimalarial suspension containing artemether and lumefantrine. It is used for the treatment of uncomplicated malaria caused by susceptible Plasmodium falciparum parasites and should be taken according to body weight and medical advice.

• Manufacturer Name: Hilton
• Drug Class: Artemisinin-based combination antimalarial
• Dosage Form: Oral Suspension
• Storage: Store at room temperature, protected from excessive heat, moisture, and direct light. Keep tightly closed and out of the reach of children.
• Pack Size: Pack of 1 Suspension

Artem Plus 15/90 Suspension 60ml Available Online in Pakistan

Dwatson offers Artem Plus 15/90 Suspension 60ml at Rs. 445, with fast, discreet delivery across Pakistan.

Ingredients

• Artemether 15 mg per 5 mL
• Lumefantrine 90 mg per 5 mL

Benefits

• Treatment of uncomplicated malaria, particularly uncomplicated Plasmodium falciparum malaria.
• Used for malaria parasites that are resistant to other antimalarial medicines.
• Not intended as sole treatment for severe or cerebral malaria.

Usage & Safety

For Adult

• For adults and patients weighing 35 kg or more: 26.7 mL per dose for 6 doses over 3 days.
• Take the first dose at diagnosis, the second dose 8 hours later, then one dose twice daily on days 2 and 3.
• Shake well before measuring each dose and take with food or a milky drink containing fat to improve absorption.
• Use only under medical supervision and complete the full treatment course.

For Children

• For children weighing 5 to less than 15 kg: 6.7 mL per dose for 6 doses over 3 days.
• For children weighing 15 to less than 25 kg: 13.3 mL per dose for 6 doses over 3 days.
• For children weighing 25 to less than 35 kg: 20 mL per dose for 6 doses over 3 days.
• For children weighing 35 kg or more: 26.7 mL per dose for 6 doses over 3 days.
• Children below 5 kg, infants, and children with suspected severe malaria require specialist assessment before treatment.
• Measure doses with an accurate oral syringe or measuring device rather than a household spoon.

Side Effects

• Common effects may include nausea, vomiting, abdominal pain, diarrhea, reduced appetite, headache, dizziness, weakness, cough, or fever.
• Temporary changes in liver enzymes or blood cell counts may occur.
• Seek urgent medical care for fainting, palpitations, severe dizziness, seizures, severe rash, facial swelling, breathing difficulty, persistent vomiting, or yellowing of the skin or eyes.
• Medical review is required if fever or malaria symptoms persist or return after treatment.

Contraindications

• Do not use in patients with known allergy to artemether, lumefantrine, or any formulation ingredient.
• Avoid use in patients with congenital long-QT syndrome, significant heart rhythm problems, severe bradycardia, or clinically important electrolyte abnormalities unless specifically directed by a specialist.
• Do not use for severe, complicated, or cerebral malaria as a substitute for parenteral antimalarial treatment.
• Avoid concomitant use with strong CYP3A4 enzyme inducers or medicines known to substantially prolong the QT interval.
• Use cautiously in significant liver disease, kidney disease, or when there is a history of fainting or irregular heartbeat.

Precautions & Warnings

• Do not combine with rifampicin, carbamazepine, phenytoin, phenobarbital, or St. John’s wort unless specifically approved by a clinician, as these may reduce antimalarial effectiveness.
• Use caution with medicines that prolong the QT interval, including some antiarrhythmics, antipsychotics, antidepressants, macrolide antibiotics, and fluoroquinolone antibiotics.
• Strong CYP3A4 inhibitors may increase exposure and adverse effects; consult a clinician before use with such medicines.
• Take with food or a fatty drink to improve lumefantrine absorption. Avoid taking it on an empty stomach when possible.
• Tell the prescriber about all antiretroviral, cardiac, anticonvulsant, antifungal, and herbal medicines.

Pregnancy

• Malaria during pregnancy can be serious and requires prompt medical treatment.
• Use during pregnancy only when prescribed after weighing the benefits and risks; treatment choices may differ by trimester and local guidelines.
• Available clinical data have not shown a clear increase in major adverse pregnancy outcomes, but first-trimester use requires individual medical assessment.
• Breastfeeding generally does not need to be stopped when treatment is medically necessary, but the infant’s age, weight, and clinical condition should be considered.